Momenta Pharmaceuticals, Inc. (MNTA) Deutsche Bank BioFEST December 05, 2011 9:00 a.m. ET Executives Rick Shea - SVP and CFO Ganesh Venkataraman - CSO, SVP, Research and Co-Founder Analysts Robyn Karnauskas - Deutsche Bank Securities PresentationRobyn Karnauskas - Deutsche Bank Securities
Thank you all for joining us and for those of you on the webcast. I am Robyn Karnauskas. And next, we have Momenta Pharmaceuticals. And it’s my pleasure to introduce, not only Rick Shea, the CFO, but also Ganesh Venkataraman – did I say that correctly – which is the one of the founders and chief scientific officer of Momenta. And actually for those of you who are listening on the webcast, if you want to email me any questions, firstname.lastname@example.org. So with Ganesh here, he could answer any questions around their acquisition this morning and around some of the science behind Momenta. And for those of you in the audience, again, we’re trying to use the DB app to sort of get some real-time feedback on the conference. So with that, we’ll start off talking about – talking about Lovenox, first of all. You guys have been very successful with defending your patents. Maybe talk a little bit about -- you've got several cases actually ongoing. Maybe just give everyone in the audience an update on when is the next data point for each of those court cases? When we’re going to hear. Rick Shea So as you know we have been – in response to Amphastar’s approval for generic Lovenox on September 19, we sued Amphastar and Watson under our patents and obtained initially a temporary restraining order and then a temporary injunction against Amphastar and Watson, preventing them from launching.